Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.39 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894269 | 0.77 | ALDH1A1 (0.42) | NPSR1PIK3CGPIK3CDPIK3C3PIK3CB | |
| SCHEMBL1616237 | 0.75 | IMPDH2 (0.48) | NPSR1PIK3CGPIK3CDPIK3C3PIK3CB | |
| SCHEMBL2625715 | 0.71 | LRRK2 (0.45) | PIK3CGPIK3CDPIK3C3PIK3CBMTOR | |
| SCHEMBL19730877 | 0.69 | APP (0.50) | PIK3CGPIK3CDPIK3C3PIK3CBAOC3 | |
| SCHEMBL3781954 | 0.68 | CYP3A4 (0.42) | — | |
| SCHEMBL2625713 | 0.68 | IMPDH2 (0.36) | — | |
| SCHEMBL12947929 | 0.67 | MAP4K4 (0.50) | AOC3SMN1; SMN2ADORA2A | |
| SCHEMBL12947909 | 0.66 | ALDH1A1 (0.43) | NPSR1PIK3CGPIK3CDPIK3C3PIK3CB | |
| SCHEMBL2409689 | 0.66 | MAPT (0.46) | NPSR1PIK3CGPIK3CDPIK3C3PIK3CB | |
| SCHEMBL792457 | 0.66 | ALDH1A1 (0.52) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094311-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LTD (GB) | 2015-04-02 | — | — | US | disclosed |
| US-8946426-B2 | Substituted bicyclic heterocyclic compounds as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| WO-2010089292-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | NPSR1 670/4885PIK3CG 900/4885PIK3CD 792/4885 |
| US-20150094311-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | NPSR1 670/4885PIK3CG 900/4885PIK3CD 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.